Aurinia Pharmaceuticals Inc.
AUPH · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $235,133 | $175,513 | $134,030 | $45,605 |
| % Growth | 34% | 31% | 193.9% | – |
| Cost of Goods Sold | $28,248 | $14,148 | $5,664 | $1,091 |
| Gross Profit | $206,885 | $161,365 | $128,366 | $44,514 |
| % Margin | 88% | 91.9% | 95.8% | 97.6% |
| R&D Expenses | $20,785 | $49,641 | $44,988 | $51,139 |
| G&A Expenses | $157,934 | $195,036 | $196,371 | $171,438 |
| SG&A Expenses | $172,028 | $195,036 | $196,371 | $171,438 |
| Sales & Mktg Exp. | $14,094 | $0 | $0 | $0 |
| Other Operating Expenses | $18,759 | $8,379 | -$1,523 | $2,672 |
| Operating Expenses | $211,572 | $253,056 | $239,836 | $225,249 |
| Operating Income | -$4,687 | -$91,691 | -$111,470 | -$180,735 |
| % Margin | -2% | -52.2% | -83.2% | -396.3% |
| Other Income/Exp. Net | $12,135 | $14,222 | $5,118 | $529 |
| Pre-Tax Income | $7,448 | -$77,469 | -$106,352 | -$180,206 |
| Tax Expense | $1,696 | $551 | $1,828 | $760 |
| Net Income | $5,752 | -$78,020 | -$108,180 | -$180,966 |
| % Margin | 2.4% | -44.5% | -80.7% | -396.8% |
| EPS | 0.04 | -0.54 | -0.76 | -1.4 |
| % Growth | 107.4% | 28.9% | 45.7% | – |
| EPS Diluted | 0.039 | -0.54 | -0.76 | -1.4 |
| Weighted Avg Shares Out | 143,057 | 143,236 | 141,915 | 129,369 |
| Weighted Avg Shares Out Dil | 146,194 | 143,236 | 141,915 | 129,369 |
| Supplemental Information | – | – | – | – |
| Interest Income | $16,970 | $16,997 | $5,118 | $529 |
| Interest Expense | $4,835 | $2,775 | $0 | $0 |
| Depreciation & Amortization | $19,445 | $11,647 | $2,706 | $2,761 |
| EBITDA | $31,728 | -$63,047 | -$103,646 | -$177,445 |
| % Margin | 13.5% | -35.9% | -77.3% | -389.1% |